Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 4

If you haven’t heard of a tardigrade before, prepare to be wowed. These clumsy, eight-legged creatures, nicknamed water bears, are about half a millimeter long and can survive practically anything: freezing temperatures, near starvation, high pressure, radiation exposure, outer space and more. Researchers reporting in the journal Nano Letters took advantage of the tardigrade’s nearly indestructible nature and gave the critters tiny “tattoos” to test a microfabrication technique to build microscopic, biocompatible devices.

“Through this technology, we’re not just creating micro-tattoos on tardigrades—we’re extending this capability to various living organisms, including bacteria,” explains Ding Zhao, a co-author of the paper.

Microfabrication has revolutionized electronics and photonics, creating micro-and nanoscale devices ranging from microprocessors and solar cells to biosensors that detect food contamination or cancerous cells. But the technology could also advance medicine and , if researchers can adapt to make them compatible with the biological realm.

Read more | >

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions—but there is always room for improvement. A new paper by investigators from Mass General Brigham showcases the power of scalable protein engineering combined with machine learning to boost progress in the field of gene and cell therapy.

In their study, the authors developed a machine learning algorithm—known as PAMmla—that can predict the properties of approximately 64 million enzymes. The work could help reduce off-target effects and improve editing safety, enhance editing efficiency, and enable researchers to predict customized enzymes for new therapeutic targets. The results are published in Nature.

“Our study is a first step in dramatically expanding our repertoire of effective and safe CRISPR-Cas9 enzymes. In our manuscript, we demonstrate the utility of these PAMmla-predicted enzymes to precisely edit disease-causing sequences in primary and in mice,” said corresponding author Ben Kleinstiver, Ph.D., Kayden-Lambert MGH Research Scholar associate investigator at Massachusetts General Hospital (MGH).

Read more | >

Genome editing has advanced at a rapid pace with promising results for treating genetic conditions-but there is always room for improvement. A new paper by investigators from Mass General Brigham published in Nature showcases the power of scalable protein engineering combined with machine learning to boost progress in the field of gene and cell therapy. In their study, authors developed a machine learning algorithm-known as PAMmla-that can predict the properties of about 64 million genome editing enzymes. The work could help reduce off-target effects and improve editing safety, enhance editing efficiency, and enable researchers to predict customized enzymes for new therapeutic targets. Their results are published in Nature.

“Our study is a first step in dramatically expanding our repertoire of effective and safe CRISPR-Cas9 enzymes. In our manuscript we demonstrate the utility of these PAMmla-predicted enzymes to precisely edit disease-causing sequences in primary human cells and in mice,” said corresponding author Ben Kleinstiver, PhD, Kayden-Lambert MGH Research Scholar associate investigator at Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system. “Building on these findings, we are excited to have these tools utilized by the community and also apply this framework to other properties and enzymes in the genome editing repertoire.”

CRISPR-Cas9 enzymes can be used to edit genes at locations throughout the genomes, but there are limitations to this technology. Traditional CRISPR-Cas9 enzymes can have off-target effects, cleaving or otherwise modifying DNA at unintended sites in the genome. The newly published study aims to improve this by using machine learning to better predict and tailor enzymes to hit their targets with greater specificity. The approach also offers a scalable solution-other attempts at engineering enzymes have had a lower throughput and typically yielded orders of magnitude fewer enzymes.

Read more | >

University of Queensland researchers have set a world record for solar cell efficiency with eco-friendly perovskite technology. A team led by Professor Lianzhou Wang has unveiled a tin halide perovskite (THP) solar cell capable of converting sunlight to electricity at a certified record efficiency of 16.65%. The research is published in the journal Nature Nanotechnology.

Working across UQ’s Australian Institute for Bioengineering and Nanotechnology and the School of Chemical Engineering, Professor Wang said the certified reading achieved by his lab was nearly one percentage point higher than the previous best for THP solar cells.

“It might not seem like much, but this is a giant leap in a field that is renowned for delicate and incremental progress,” Professor Wang said.

Read more | >

Scientists from Mass General Brigham and Beth Israel Deaconess Medical Center have developed a novel gene editing tool called STITCHR. Unlike traditional CRISPR, STITCHR inserts entire genes at precise locations, minimizing unintended mutations. This gene editing tool simplifies use and offers potential as a one-time treatment for genetic disorders.

The technology uses retrotransposons, naturally occurring “jumping genes” found in all eukaryotic organisms, which can move and integrate into genomes. Using computational screening, the researchers identified and reprogrammed a specific retrotransposon to work with the nickase enzyme from CRISPR, forming the complete STITCHR system that allows a precise, seamless gene insertion into the genome.

STITCHR offers the potential to replace or supplement entire genes, creating a more universal treatment option for various genetic diseases. The research team is now working to improve its efficiency and move it toward clinical use. Their study, published in Nature, highlights how insights from basic cellular biology can drive innovation in genetic medicine and lead to new therapeutic tools.

Read more | >

While CRISPR-mediated gene editing has led to powerful advances across biology, medicine, and agriculture, challenges persist in optimizing the editing efficiency of enzymes, such as the widely used Cas9 nuclease. This is especially true in therapeutic use cases, where the goal is to attain high rates of editing via a relatively low and transient enzyme dose.

In a new study published in the April 2025 issue of The CRISPR Journal titled, “Hairpin Internal Nuclear Localization Signals in CRISPR-Cas9 Enhance Editing in Primary Human Lymphocytes,” researchers from the Innovative Genomics Institute (IGI) at the University of California (UC), Berkeley, present a strategy to improve editing efficiency in human immune cells for therapeutic applications by leveraging new constructs for nuclear localization signal (NLS) sequences.

“Efficient CRISPR enzyme production is essential for translation. This is one element that allowed the rapid clinical evaluation of Casgevy, the world’s first genome editing drug. Unfortunately, this aspect tends to be overlooked in the basic research performed in academia,” said Ross Wilson, PhD, assistant adjunct professor of molecular and cell biology at UC Berkeley, who led the new study.

Read more | >

Northeastern University researchers resurrected an extinct plant gene, turning back the evolutionary clock to pave a path forward for the development and discovery of new drugs.

Specifically, the team, led by Jing-Ke Weng, a professor of chemistry, and bioengineering at Northeastern, repaired a defunct gene in the coyote tobacco plant.

In a new paper, they detail their discovery of a previously unknown kind of cyclic peptide, or mini-protein, called nanamin that is easy to bioengineer, making it “a platform with huge potential for drug discovery,” Weng says. The paper is published in the journal Proceedings of the National Academy of Sciences.

Read more | >